gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2022-32-1-46-52gastro-j-720Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГОВ, ГЕПАТОЛОГОВNATIONAL COLLEGE OF GASTROENTEROLOGISTS, HEPATOLOGISTSМетаболомные профили как новое понимание процессов болезниMetabolomic profiles as a new understanding of disease processeshttps://orcid.org/0000-0002-6701-789XЗольниковаО. Ю.ZolnikovaO. Yu.

Зольникова Оксана Юрьевна — доктор медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии.

119435, Москва, ул. Погодинская, д. 1, стр. 1.

Oxana Yu. Zolnikova — Dr.  Sci.  (Med.),  Associate Prof., Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).

119435, Moscow, Pogodinskaya str., 1, bld. 1.

zolnikova_o_yu@staff.sechenov.ruhttps://orcid.org/0000-0001-9276-6924РешетоваМ. С.ReshetovaM. S.

Решетова Мария Сергеевна — аспирант кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии.

119435, Москва, ул. Погодинская, д. 1, стр. 1.

Maria S. Reshetova — graduate student, Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).

119435, Moscow, Pogodinskaya str., 1, bld. 1.

maria.reshetova@icloud.comhttps://orcid.org/0000-0002-7157-6627ИвановаМ. Н.IvanovaM. N.

Иванова Марина Николаевна — аспирант кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии.

119435, Москва, ул. Погодинская, д. 1, стр. 1.

Marina N. Ivanova — graduate student, Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).

119435, Moscow, Pogodinskaya str., 1, bld. 1.

schtern93@mail.ruhttps://orcid.org/0000-0002-6815-6015ИвашкинВ. Т.IvashkinV. T.

Ивашкин Владимир Трофимович — доктор медицинских наук, профессор, академик РАН, заведующий кафедрой пропедевтики   внутренних   болезней,    гастроэнтерологии и гепатологии.

119435, Москва, ул. Погодинская, д. 1, стр. 1.

Vladimir T. Ivashkin — Dr. Sci. (Med.), RAS Academician, Prof., Department Head, Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, I.M. Sechenov First Moscow State Medical University (Sechenov University).

119435, Moscow, Pogodinskaya str., 1, bld. 1.

ivashkin_v_t@staff.sechenov.ruПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет) Министерства здравоохранения Российской ФедерацииРоссияSechenov First Moscow State University (Sechenov University)Russian Federation2022240520223214652Copyright © Зольникова О.Ю., Решетова М.С., Иванова М.Н., Ивашкин В.Т., 20222022Зольникова О.Ю., Решетова М.С., Иванова М.Н., Ивашкин В.Т.Zolnikova O.Y., Reshetova M.S., Ivanova M.N., Ivashkin V.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/720Цель обзора

Цель обзора: представить информацию о возможностях применения метаболомного профилирования для выявления биомаркеров различных заболеваний внутренних органов.

Основные положения

Основные положения. Новое диагностическое направление связано с высокочувствительным спектральным анализом молекул-биомаркеров. В обзоре литературы обсуждаются некоторые из последних достижений с акцентом на применение метаболомики для выявления основных метаболомных изменений при различных заболеваниях. Обсуждается возможность поиска диагностических маркеров при заболеваниях желудочно-кишечного тракта, респираторной и сердечно-сосудистой систем, в онкологии, эндокринологии, неврологии. Эти результаты определяют и новые потенциальные терапевтические стратегии, делая метаболомику полезной для широкого круга биомедицинских и фармацевтических исследований.

Заключение

Заключение. Новые данные об изменении метаболомного профиля при разных нозологических формах помогут улучшить понимание патогенеза заболеваний. И разработать новые терапевтические подходы в лечении, учитывая данные индивидуальных характеристик пациента, выявляемые с помощью актуальных молекулярных технологий. Результаты метаболомных исследований могут быть применимы и в качестве мониторинга результатов лечения.

Aim

Aim. This review will demonstrate possibilities of using metabolomic profiling to identify biomarkers of various internal organs diseases.

Key points

Key points. A new diagnostic direction is associated with high-sensitive spectral analysis of biomarker molecules. This review will discuss some of the latest advances with an emphasis on the use of metabolomics to identify major metabolic changes in various diseases. The possibility of finding diagnostic markers in diseases of the gastrointestinal tract, respiratory and cardiovascular systems, in oncology, endocrinology, neurology are discussed. These results define new potential therapeutic strategies, making metabolomics useful for a wide range of biomedical and pharmaceutical research.

Conclusion

Conclusion. Metabolomic profile changes in different types of diseases will help to improve understanding of the pathogenesis. New therapeutic approaches may be developed. They will take into account individual characteristics of the patient, identified by using current molecular technologies. The results of metabolomic studies can be used to monitor treatment outcomes.

метаболитыметаболомное профилированиебиомаркерымасс-спектрометрияжидкостная хроматографиямониторинг леченияmetabolitesmetabolomic profilingbiomarkersmassspectrometryliquid chromatographytreatment monitoringReferencesWishart D. Emerging applications of metabolomics in drug discovery and precision medicine Nat Rev Drug Discov. 2016;15(7):473–84. DOI: 10.1038/nrd.2016.32Wishart D. Emerging applications of metabolomics in drug discovery and precision medicine Nat Rev Drug Discov. 2016;15(7):473–84. DOI: 10.1038/nrd.2016.32van de Velde B., Guillarme D., Kohler I. Supercritical fluid chromatography — Mass spectrometry in metabolomics: Past, present, and future perspectives. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1161:122444. DOI: 10.1016/j.jchromb.2020.122444van de Velde B., Guillarme D., Kohler I. Supercritical fluid chromatography — Mass spectrometry in metabolomics: Past, present, and future perspectives. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1161:122444. DOI: 10.1016/j.jchromb.2020.122444Kelly R.S., Kelly M.P., Kelly P.Т. Metabolomics, physical activity, exercise and health: A review of the current evidence. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165936. DOI: 10.1016/j.bbadis.2020.165936Kelly R.S., Kelly M.P., Kelly P.Т. Metabolomics, physical activity, exercise and health: A review of the current evidence. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165936. DOI: 10.1016/j.bbadis.2020.165936Ghosh T., Philtron D., Zhang W., Kechris K., Ghosh D. Reproducibility of mass spectrometry based metabolomics data. BMC Bioinformatics. 2021;22(1):423. DOI: 10.1186/s12859-021-04336-9Ghosh T., Philtron D., Zhang W., Kechris K., Ghosh D. Reproducibility of mass spectrometry based metabolomics data. BMC Bioinformatics. 2021;22(1):423. DOI: 10.1186/s12859-021-04336-9Kondoh H., Kameda M., Yanagida M. Whole Blood Metabolomics in Aging Research. Int J Mol Sci. 2020;22(1):175. DOI: 10.3390/ijms22010175Kondoh H., Kameda M., Yanagida M. Whole Blood Metabolomics in Aging Research. Int J Mol Sci. 2020;22(1):175. DOI: 10.3390/ijms22010175Ma C., Tian B., Wang J., Yang G., Pan C., Lu J. Metabolic characteristics of acute necrotizing pancreatitis and chronic pancreatitis. Mol Med Rep. 2012;6(1):57–62. DOI: 10.3892/mmr.2012.881Ma C., Tian B., Wang J., Yang G., Pan C., Lu J. Metabolic characteristics of acute necrotizing pancreatitis and chronic pancreatitis. Mol Med Rep. 2012;6(1):57–62. DOI: 10.3892/mmr.2012.881Díaz C., Jiménez-Luna C., Diéguez-Castillo C. Untargeted metabolomics for the diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis. Med. 2021;57(9):1–9. DOI: 10.3390/medicina57090876Díaz C., Jiménez-Luna C., Diéguez-Castillo C. Untargeted metabolomics for the diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis. Med. 2021;57(9):1–9. DOI: 10.3390/medicina57090876Franzosa E.A., Sirota-Madi A., Avila-Pacheco J. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4(2):293–305. DOI: 10.1038/s41564-018-0306-4Franzosa E.A., Sirota-Madi A., Avila-Pacheco J. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4(2):293–305. DOI: 10.1038/s41564-018-0306-4Gallagher K., Catesson A., Griffin J., Holmes E., Williams H. Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review. 2021;15(5):813–26. DOI: 10.1093/ecco-jcc/jjaa227Gallagher K., Catesson A., Griffin J., Holmes E., Williams H. Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review. 2021;15(5):813–26. DOI: 10.1093/ecco-jcc/jjaa227Ситкин С.И., Ткаченко Е.И., Вахитов Т.Я., Орешко Л.С., Жигалова Т.Н., Авалуева Е.Б. Метаболом сыворотки крови и микробиота кишечника при язвенном колите и целиакии. Вестник Северо-западного государственного медицинского университета имени И.И. Мечникова. 2014;3:12–23.Sitkin S.I., Tkachenko E.I., Vakhitov T.Ya., Oreshko L.S., Zhigalova T.N., Avalueva E.B. Serum metabolome and intestinal microbiota in ulcerative colitis and celiac disease. Bulletin of the North-Western State Medical University named after I.I. Mechnikov. 2014;3:12–23 (In Russ.).Masarone M., Troisi J., Aglitti A., Torre P., Colucci A., Dallio M. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. Metabolomics. 2021;17(2):12. DOI: 10.1007/s11306-020-01756-1Masarone M., Troisi J., Aglitti A., Torre P., Colucci A., Dallio M. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. Metabolomics. 2021;17(2):12. DOI: 10.1007/s11306-020-01756-1Nimer N., Choucair I., Wang Z., Nemet I., Li L., Gukasyan J. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism. 2020; 116:154457. DOI: 10.1016/j.metabol.2020.154457Nimer N., Choucair I., Wang Z., Nemet I., Li L., Gukasyan J. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism. 2020; 116:154457. DOI: 10.1016/j.metabol.2020.154457Анохина Т.Н., Анаев Э.Х., Чучалин А.Г., Ревельский А.И., Родионов А.А., Ревельский И.А. и др. Метаболомный подход в диагностике бронхиальной астмы и хронической обструктивной болезни легких. Российский биомедицинский журнал. 2011;4:1266–77.Anokhina T.N., Anaev E.Kh., Chuchalin A.G., Revelsky A.I., Rodionov A.A., Revelsky I.A., et al. Metabolomic approach in the diadnosis of astma and COPD. Russian Biomedical Journal. 2011;4:1266–77 (In Russ.).Bowerman K., Rehman S., Vaughan A., Lachner N., Budden K. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun. 2020;11(1):5886. DOI: 10.1038/s41467-020-19701-0Bowerman K., Rehman S., Vaughan A., Lachner N., Budden K. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun. 2020;11(1):5886. DOI: 10.1038/s41467-020-19701-0Zhu Т., Li S., Wang J., Liu Ch, Gao L., Zeng Yu., et al. Induced sputum metabolomic profiles and oxidative stress are associated with chronic obstructive pulmonary disease (COPD) severity: potential use for predictive, preventive, and personalized medicine. EPMA J. 2020;11(4):645–59. DOI: 10.1007/s13167-020-00227-wZhu Т., Li S., Wang J., Liu Ch, Gao L., Zeng Yu., et al. Induced sputum metabolomic profiles and oxidative stress are associated with chronic obstructive pulmonary disease (COPD) severity: potential use for predictive, preventive, and personalized medicine. EPMA J. 2020;11(4):645–59. DOI: 10.1007/s13167-020-00227-wAlbornoz A., Alarcon P., Morales N., Uberti B., Henriquez C., Manosalva C., et al. Metabolomics analysis of bronchoalveolar lavage fluid samples in horses with naturally-occurring asthma and experimentally-induced airway inflammation. Res Vet Sci. 2020;133:276–82. DOI: 10.1016/j.rvsc.2020.09.033Albornoz A., Alarcon P., Morales N., Uberti B., Henriquez C., Manosalva C., et al. Metabolomics analysis of bronchoalveolar lavage fluid samples in horses with naturally-occurring asthma and experimentally-induced airway inflammation. Res Vet Sci. 2020;133:276–82. DOI: 10.1016/j.rvsc.2020.09.033Villaseñor A., Eguiluz-Gracia I., Moreira A., Wheelock C.E., Escribese M.M. Metabolomics in the Identification of Biomarkers of Asthma. Metabolites. 2021;11(6):346. DOI: 10.3390/metabo11060346Villaseñor A., Eguiluz-Gracia I., Moreira A., Wheelock C.E., Escribese M.M. Metabolomics in the Identification of Biomarkers of Asthma. Metabolites. 2021;11(6):346. DOI: 10.3390/metabo11060346Lee-Sarwar K.A., Kelly R.S., Lasky-Su J., Zeiger R.S., O’Connor G.T., Sandel M.T., et al. Integrative analysis of the intestinal metabolome of childhood asthma. J Allergy Clin Immunol. 2019;144(2):442–54. DOI: 10.1016/j.jaci.2019.02.032Lee-Sarwar K.A., Kelly R.S., Lasky-Su J., Zeiger R.S., O’Connor G.T., Sandel M.T., et al. Integrative analysis of the intestinal metabolome of childhood asthma. J Allergy Clin Immunol. 2019;144(2):442–54. DOI: 10.1016/j.jaci.2019.02.032Ivashkin V., Zolnikova O., Potskherashvili N., Trukhmanov A., Kokina N., Dzhakhaya N., et al. A metabolic activity of the intestinal microflora in patients with bronchial asthma. Clinics and Practice. 2019;9:1126. DOI: 10.4081/cp.2019.1126Ivashkin V., Zolnikova O., Potskherashvili N., Trukhmanov A., Kokina N., Dzhakhaya N., et al. A metabolic activity of the intestinal microflora in patients with bronchial asthma. Clinics and Practice. 2019;9:1126. DOI: 10.4081/cp.2019.1126Xu S., Panettieri R., Jude J. Metabolomics in asthma: A platform for discovery. Mol Aspects Med. 2021;3:100990. DOI: 10.1016/j.mam.2021.100990Xu S., Panettieri R., Jude J. Metabolomics in asthma: A platform for discovery. Mol Aspects Med. 2021;3:100990. DOI: 10.1016/j.mam.2021.100990Wang C., Jiang S., Zhang S., Ouyang Z., Wang G., Wang F. Research Progress of Metabolomics in Asthma. Metabolites. 2021;11(9):567. DOI: 10.3390/meta-bo11090567Wang C., Jiang S., Zhang S., Ouyang Z., Wang G., Wang F. Research Progress of Metabolomics in Asthma. Metabolites. 2021;11(9):567. DOI: 10.3390/meta-bo11090567Papamichael M., Katsardis C., Sarandi E., Georgaki S., Frima E.S., Varvarigou A. et al. Application of Metabolomics in Pediatric Asthma: Prediction, Diagnosis and Personalized Treatment. Metabolites. 2021;11(4):251. DOI: 10.3390/metabo11040251Papamichael M., Katsardis C., Sarandi E., Georgaki S., Frima E.S., Varvarigou A. et al. Application of Metabolomics in Pediatric Asthma: Prediction, Diagnosis and Personalized Treatment. Metabolites. 2021;11(4):251. DOI: 10.3390/metabo11040251Hasegawa K., Stewart C.J., Celedón J.C., Mansbach J.M., Tierney C., Camargo C.A. Serum 25-hydroxyvitamin D, metabolome, and bronchiolitis severity among infants-A multicenter cohort study. Pediatr Allergy Immunol. 2018;29(4):441–5. DOI: 10.1111/pai.12880Hasegawa K., Stewart C.J., Celedón J.C., Mansbach J.M., Tierney C., Camargo C.A. Serum 25-hydroxyvitamin D, metabolome, and bronchiolitis severity among infants-A multicenter cohort study. Pediatr Allergy Immunol. 2018;29(4):441–5. DOI: 10.1111/pai.12880Grassin-Delyle S., Roquencourt C., Moine P., Saffroy G., Carn S., Heming N. Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study. EBioMedicine. 2021;63:103154. DOI: 10.1016/j.ebiom.2020.103154Grassin-Delyle S., Roquencourt C., Moine P., Saffroy G., Carn S., Heming N. Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study. EBioMedicine. 2021;63:103154. DOI: 10.1016/j.ebiom.2020.103154Tang W.H., Wang Z., Levison B.S., Koeth R.A., Britt E.B. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–84. DOI: 10.1056/NEJMoa1109400Tang W.H., Wang Z., Levison B.S., Koeth R.A., Britt E.B. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–84. DOI: 10.1056/NEJMoa1109400Amin A.M. Metabolomics applications in coronary artery disease personalized medicine. Adv Clin Chem. 2021;102:233–70. DOI: 10.1016/bs.acc.2020.08.003Amin A.M. Metabolomics applications in coronary artery disease personalized medicine. Adv Clin Chem. 2021;102:233–70. DOI: 10.1016/bs.acc.2020.08.003Murthy V.L., Reis J.P., Pico A.R., Kitchen R., Lima J.A., Lloyd-Jones D., et al. Comprehensive Metabolic Phenotyping Refines Cardiovascular Risk in Young Adults. Circulation. 2020;142(22):2110–27. DOI: 10.1161/CIRCULATIONAHA.120.047689Murthy V.L., Reis J.P., Pico A.R., Kitchen R., Lima J.A., Lloyd-Jones D., et al. Comprehensive Metabolic Phenotyping Refines Cardiovascular Risk in Young Adults. Circulation. 2020;142(22):2110–27. DOI: 10.1161/CIRCULATIONAHA.120.047689Koeth R. A., Wang Z., Levison B., Buffa J., Org E., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013;19:576–85. DOI: 10.1038/nm.3145Koeth R. A., Wang Z., Levison B., Buffa J., Org E., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013;19:576–85. DOI: 10.1038/nm.3145Wang Z., Tang W., Buffa J., Fu X., Britt E., et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014:35;904–10. DOI: 10.1093/eurheartj/ehu002Wang Z., Tang W., Buffa J., Fu X., Britt E., et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014:35;904–10. DOI: 10.1093/eurheartj/ehu002Nayor M., Brown K.J., Vasan R.S. The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk. Circ Res. 2021;128(2):287–303. DOI: 10.1161/CIRCRESAHA.120.315890Nayor M., Brown K.J., Vasan R.S. The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk. Circ Res. 2021;128(2):287–303. DOI: 10.1161/CIRCRESAHA.120.315890Warrier M., Shih D., Burrows A., Ferguson D., Gromovsky A., Brown A., et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. 2015;10:326–38. DOI: 10.1016/j.celrep.2014.12.036Warrier M., Shih D., Burrows A., Ferguson D., Gromovsky A., Brown A., et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. 2015;10:326–38. DOI: 10.1016/j.celrep.2014.12.036Chen X., Liu L., Palacios G. Plasma metabolomics reveals biomarkers of the atherosclerosis. Journal of Separation Science. 2010;33:2776–83. DOI: 10.1002/jssc.201000395Chen X., Liu L., Palacios G. Plasma metabolomics reveals biomarkers of the atherosclerosis. Journal of Separation Science. 2010;33:2776–83. DOI: 10.1002/jssc.201000395Deidda M., Piras C., Dessalvi C. Metabolomic approach to functional and metabolic myocardial changes in heart failure. Journal of Translational Medicine. 2015;13:297. DOI: 10.1186/s12967-015-0661-3Deidda M., Piras C., Dessalvi C. Metabolomic approach to functional and metabolic myocardial changes in heart failure. Journal of Translational Medicine. 2015;13:297. DOI: 10.1186/s12967-015-0661-3Zordoky B.N., Sung M.M., Ezekowitz J. Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. PLoS ONE. 2015;10(5):e0124844. DOI: 10.1371/journal.pone. 0124844Zordoky B.N., Sung M.M., Ezekowitz J. Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. PLoS ONE. 2015;10(5):e0124844. DOI: 10.1371/journal.pone. 0124844Wishart D.S. Is cancer a genetic disease or a metabolic disease? EBioMedicine. 2015;2(6):478–9. DOI: 10.1016/j.ebiom.2015.05.022Wishart D.S. Is cancer a genetic disease or a metabolic disease? EBioMedicine. 2015;2(6):478–9. DOI: 10.1016/j.ebiom.2015.05.022Qu W., Oya S., Lieberman B., Ploessl K., Wang L., et al. Preparation and characterization of L-[5-11C]-glutamine for metabolic imaging of tumors. J Nucl Med. 2012;53(1):98–105. DOI: 10.2967/jnumed.111.093831Qu W., Oya S., Lieberman B., Ploessl K., Wang L., et al. Preparation and characterization of L-[5-11C]-glutamine for metabolic imaging of tumors. J Nucl Med. 2012;53(1):98–105. DOI: 10.2967/jnumed.111.093831Losman J.A., Looper R., Koivunen P. (R)-2-hydroxy-glutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621–5. DOI: 10.1126/science.1231677Losman J.A., Looper R., Koivunen P. (R)-2-hydroxy-glutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621–5. DOI: 10.1126/science.1231677Zhu L., Ploessl K., Zhou R., Mankoff D., Kung H. Metabolic Imaging of Glutamine in Cancer. J Nucl Med. 2017;58(4):533–7. DOI: 10.2967/jnumed.116.182345Zhu L., Ploessl K., Zhou R., Mankoff D., Kung H. Metabolic Imaging of Glutamine in Cancer. J Nucl Med. 2017;58(4):533–7. DOI: 10.2967/jnumed.116.182345Лисица А.В., Пономаренко Е.А., Лохов П.Г., Арчаков А.И. Постгеномная медицина: альтернатива биомаркерам. Вестник РАМН. 2016;71(3):255–60. DOI: 10.15690/vramn64Lisitsa A.V., Ponomarenko E.A., Lokhov P.G., Archakov A.I. Postgenomic Medicine: Alternative to Biomarkers. Annals of the Russian Academy of Medical Sciences. 2016;71(3):255–60 (In Russ.). DOI: 10.15690/vramn64Davis V.W., Schiller D.E., Eurich D. Urinary metabolomic signature of esophageal cancer and Barrett’s esophagus. World J Surg Onc. 2021;10:271. DOI: 10.1186/1477-7819-10-271Davis V.W., Schiller D.E., Eurich D. Urinary metabolomic signature of esophageal cancer and Barrett’s esophagus. World J Surg Onc. 2021;10:271. DOI: 10.1186/1477-7819-10-271Bhatt A.P., Redinbo M.R., Bultman S.J. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67(4):326–44. DOI: 10.3322/caac.21398Bhatt A.P., Redinbo M.R., Bultman S.J. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67(4):326–44. DOI: 10.3322/caac.21398Bar N., Korem T. , Weissbrod O., Zeevi D, Rothschildm D., et al. A reference map of potential determinants for the human serum metabolome. Nature. 2020;588(7836):135–40. DOI: 10.1038/s41586-020-2896-2Bar N., Korem T. , Weissbrod O., Zeevi D, Rothschildm D., et al. A reference map of potential determinants for the human serum metabolome. Nature. 2020;588(7836):135–40. DOI: 10.1038/s41586-020-2896-2De Angelis M., Garruti G., Minervini F., Bonfrate L., Portincasa P., Gobbetti M. The Food-gut Human Axis: The Effects of Diet on Gut Microbiota and Metabolome. Curr Med Chem. 2019;26(19):3567–83. DOI: 10.2174/0929867324666170428103848De Angelis M., Garruti G., Minervini F., Bonfrate L., Portincasa P., Gobbetti M. The Food-gut Human Axis: The Effects of Diet on Gut Microbiota and Metabolome. Curr Med Chem. 2019;26(19):3567–83. DOI: 10.2174/0929867324666170428103848Chen Z.Z., Gerszten R.E. Metabolomics and Proteomics in Type 2 Diabetes. Circ Res. 2020;126(11):1613–27. DOI: 10.1161/CIRCRESAHA.120.315898Chen Z.Z., Gerszten R.E. Metabolomics and Proteomics in Type 2 Diabetes. Circ Res. 2020;126(11):1613–27. DOI: 10.1161/CIRCRESAHA.120.315898Willkommen D., Lucio M., Moritz F., Forcisi S., Kanawati B., Smirnov K., et al. Metabolomic investigations in cerebrospinal fl uid of Parkinson’s disease. PLoS One. 2018;13(12):e0208752. DOI: 10.1371/journal.pone.0208752Willkommen D., Lucio M., Moritz F., Forcisi S., Kanawati B., Smirnov K., et al. Metabolomic investigations in cerebrospinal fl uid of Parkinson’s disease. PLoS One. 2018;13(12):e0208752. DOI: 10.1371/journal.pone.0208752He R., Yan X., Guo J., Xu Q., Tang B., Sun Q. Recent Advances in Biomarkers for Parkinson’s Disease. Front Aging. Neurosci. 2018;10:305. DOI: 10.3389/fnagi.2018.00305He R., Yan X., Guo J., Xu Q., Tang B., Sun Q. Recent Advances in Biomarkers for Parkinson’s Disease. Front Aging. Neurosci. 2018;10:305. DOI: 10.3389/fnagi.2018.00305Orešič M., Tang J., Seppänen-Laakso T., Mattila I., Saarni S.E., Saarni S.I., et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 2011;3(3):19. DOI: 10.1186/gm233Orešič M., Tang J., Seppänen-Laakso T., Mattila I., Saarni S.E., Saarni S.I., et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 2011;3(3):19. DOI: 10.1186/gm233Tripp B.A., Dillon S.T., Yuan M., Asara J.M., Vasunilashorn S.M., Fong T.G., et al. Targeted metabolomics analysis of postoperative delirium. Sci Rep. 2021;11(1):1521. DOI: 10.1038/s41598-020-80412-zTripp B.A., Dillon S.T., Yuan M., Asara J.M., Vasunilashorn S.M., Fong T.G., et al. Targeted metabolomics analysis of postoperative delirium. Sci Rep. 2021;11(1):1521. DOI: 10.1038/s41598-020-80412-zLiu L., Zhao J., Chen Y., Feng R. Metabolomics strategy assisted by transcriptomics analysis to identify biomarkers associated with schizophrenia. Anal Chim Acta. 2020;1140:18–29. DOI: 10.1016/j.aca.2020.09.054Liu L., Zhao J., Chen Y., Feng R. Metabolomics strategy assisted by transcriptomics analysis to identify biomarkers associated with schizophrenia. Anal Chim Acta. 2020;1140:18–29. DOI: 10.1016/j.aca.2020.09.054Wu L., Han Y., Zheng Z., Peng G., Liu P., Yue S., et al. Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Signals in Host-Microbe Interplay. Nutrients. 2021;13(1):228. DOI: 10.3390/nu13010228.Wu L., Han Y., Zheng Z., Peng G., Liu P., Yue S., et al. Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Signals in Host-Microbe Interplay. Nutrients. 2021;13(1):228. DOI: 10.3390/nu13010228.

The authors declare that there are no conflicts of interest present.